SHP1705 is a potent and selective activator of Cryptochrome 2 (CRY2). It inhibits BMAL1-CLOCK transcriptional activity and significantly enhances efficacy against glioblastoma stem cells (GSCs) and PDX tumors and can be used in research on GSC biology and survival in glioblastoma (GBM).

Duocarmycin SA is a potent antitumor antibiotic with an IC50 of 10 pM. It is an extremely potent cytotoxic agent capable of inducing a sequence-selective alkylation of duplex DNA and can be used in research treatment for glioblastoma multiforme (GBM).

Myt1-IN-1 is a potent and selective inhibitor of membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1)(Gene: PKMYT1) with an IC50 of

LY3499446 (KRASG12C IN-13) is a potent inhibitor of KRAS G12C. It can be used in research on advanced solid tumors, including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).

BKT-300 is a potent and selective inhibitor of Protein regulator of cytokinesis 1 (PRC1) with a Kd of 28.3 nM. It disrupts microtubule organization, inducing G2/M arrest, mitotic catastrophe, and caspase-3–dependent apoptosis, and shows promise as a research treatment for advanced acute myeloid leukemia (AML).

YDR1 is a potent, selective and orally bioavailable Cereblon-based PROTAC and a degrader of SMARCA2 with DC50 of 60 nM at 48 hours. It exhibits antitumor activity in SMARCA4-mutant lung cancer xenograft models and can be used in research on non-small cell lung cancer.

YD54 is a potent, selective and orally bioavailable PROTAC and a degrader of SMARCA2 with DC50 of 8.1 nM at 24 hours. It exhibits antitumor activity in SMARCA4-mutant lung cancer xenograft models and can be used in research on non-small cell lung cancer.

ABD0171 is a potent, irreversible, and selective inhibitor of aldehyde dehydrogenase 1A3 (ALDH1A3), with an IC50 of 0.34 µM using the physiological substrate all-trans-retinaldehyde (atRAL). It also inhibits ALDH1A2 and ALDH1A1 with IC50 of 0.79 µM and 6.6 µM, respectively. ABD0171 disrupts key oncogenic pathways in triple-negative breast cancer (TNBC) cells in vitro and exhibits robust antitumor and […]

GEM144 is a potent and orally active dual inhibitor of DNA polymerase α (POLA1) and HDAC11 . It exhibits potent antiproliferative activity in vitro and antitumor efficacy in vivo by inducing p53 acetylation, p21 activation, G1/S cell cycle arrest, and apoptosis.

Flezurafenib is an oral inhibitor of pan-RAF with potential antineoplastic activity.